Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/4/2024 | $70.00 | Neutral | Mizuho |
10/8/2024 | $82.00 | Buy | Stifel |
10/7/2024 | $71.00 | Neutral | Piper Sandler |
9/26/2024 | Peer Perform | Wolfe Research | |
9/5/2024 | Neutral | BTIG Research | |
6/24/2024 | Hold | Argus | |
5/30/2024 | $54.00 | Sell | Goldman |
4 - Solventum Corp (0001964738) (Issuer)
4/A - Solventum Corp (0001964738) (Reporting)
4 - Solventum Corp (0001964738) (Issuer)
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)
EFFECT - Solventum Corp (0001964738) (Filer)
POS AM - Solventum Corp (0001964738) (Filer)
EFFECT - Solventum Corp (0001964738) (Filer)
Company to host an Investor Day in March 2025ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, February 27, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investor
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company's Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio Actions and Prudent Capital Allocation NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi
Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00
Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00
Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00
Company to host an Investor Day in March 2025ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, February 27, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investor
Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company's Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio Actions and Prudent Capital Allocation NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, to
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai